Promising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential
Express News | Tenaya Therapeutics Reveals Interim Data From RIDGE Natural History And Seroprevalence Study Of Adults With PKP2-Associated ARVC At Heart Rhythm 2025
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Tenaya Therapeutics Amid Promising TN-201 Data and Financial Stability
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
Tenaya Therapeutics Announces Late Breaker Presentation Of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 At American College Of Cardiology Annual Meeting
Tenaya Therapeutics Announces Late Breaker Presentation of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Tenaya Therapeutics Announces Late Breaker Presentation of New Data From MyPEAK -1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Express News | Tenaya Therapeutics Inc - Expects to Recognize Charges by Q3 2025 - SEC Filing
Express News | Tenaya Therapeutics Inc - on Mar 27, Co Approves Restructuring Plan - SEC Filing
SA Asks: Which Small/mid-cap Cardiology Stocks Are Undervalued?
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $6
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March
Promising Developments in Tenaya Therapeutics' TN-201 Program Justify Buy Rating
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Stock Price Dropped 13% Last Week; Individual Investors Would Not Be Happy
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Express News | Tenaya Therapeutics Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing